SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-24-048952
Filing Date
2024-04-18
Accepted
2024-04-18 18:22:34
Documents
2
Period of Report
2024-04-12

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2412208-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2412208-1_3seq1.xml 3 1594
2 EXHIBIT 24 tm2412208d1_ex24.htm EX-24 10788
  Complete submission text file 0001104659-24-048952.txt   13951
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Issuer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AEON BIOPHARMA, INC. 5 PARK PLAZA, SUITE 1750 IRVINE CA 92614
Business Address
Park Seongsoo (Reporting) CIK: 0002020349 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40021 | Film No.: 24855233